News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
Sudeep Nutrition will be a one-stop solution for food, beverage, nutraceuticals and nutritional product manufacturers
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Acute therapies continue to report strong growth compared to chronic ones.
Cipla has reported consolidated financial results for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Subscribe To Our Newsletter & Stay Updated
